Oral abutment with drug sustained release function

Abstract

The invention discloses an oral abutment with a drug sustained release function, and relates to the technical field of medical implantation. In order to solve the problem of poor treatment effect caused by insufficient drug concentration in the prior art, the invention designs the oral cavity abutment with the drug sustained-release function, and the oral cavity abutment is mainly structurally characterized by having three drug release modes which are mutually matched and linked; comprising a continuous release mode structure, an inflammation release mode structure and a stress release mode structure, in a daily state, a proper amount of medicine is continuously released through an osmotic pump, and the basic treatment concentration is maintained; after the mucosa around the implant is inflamed, the temperature rise of the inflammation part is detected, and the medicine release amount is increased through an inflammation release mode structure so as to strengthen the treatment effect; when a patient presses and occludes, the drug release amount is further supplemented through the stress release mode structure. According to the invention, the treatment effect on the mucositis around the implant is obviously improved, and the repair and regeneration of tissues around the implant are promoted.

Description

Technical Field

[0001] This invention relates to the field of medical implant technology, and more specifically, to an oral abutment with drug sustained-release function. Background Technology

[0002] In the field of oral medicine, implant restoration technology has become an important treatment method for patients with missing teeth. However, peri-implant mucositis, a common complication after implant surgery, poses a potential threat to patients' oral health. Its incidence is increasing year by year, mainly due to factors such as improper oral hygiene and bacterial infection. If peri-implant mucositis is not treated promptly and effectively, it may lead to bone resorption around the implant, ultimately resulting in implant failure. This not only increases the patient's pain and financial burden but may also cause a series of oral functional disorders.

[0003] Traditional treatments for peri-implantitis typically involve local irrigation, topical medication, or oral antibiotics. Local irrigation and topical medication are inconvenient to perform, and the medication remains at the inflamed site for a short time, making it difficult to maintain an effective drug concentration. Oral antibiotics, on the other hand, can cause systemic adverse reactions, and their concentration is significantly reduced by the time they reach the peri-implantitis area, limiting their effectiveness.

[0004] In recent years, the rapid development of biomaterials science and drug controlled-release technology has provided opportunities for treatment innovation in the field of dental implantology. Smart materials, such as shape memory alloys, exhibit unique physical properties that can respond to environmental changes; osmotic pump technology has achieved significant results in drug sustained release, enabling precise and continuous drug delivery; and the utilization of physiological movements such as occlusion has provided new ideas for on-demand drug delivery. Based on the support of these advanced technologies, a novel temporary implant abutment with drug sustained-release function is proposed to overcome the shortcomings of traditional treatment methods.

[0005] Patent CN116831760B discloses an anti-inflammatory and antibacterial drug sustained-release abutment for use in dental implants. The abutment includes a wireless power receiver mounted on a phototherapy implant. A conductor rod is connected to the top of the wireless power receiver, and a base shell is connected to the surface of the wireless power receiver. The conductor rod is located inside the base shell, which can hold an anti-inflammatory and antibacterial drug solution. A drug dispensing hole is provided on the base shell, and a sealing cap is movably connected to the base shell at the position corresponding to the drug dispensing hole. This invention, by incorporating a conductor rod, conductor ring, plastic film, and sealing cap, solves the problem that existing phototherapy devices lack the storage and release function for light-activated anti-inflammatory drugs, which to some extent limits their antibacterial and anti-inflammatory efficacy, hinders the shortening of healing time, and may reduce the comfort of implant patients.

[0006] The improvement direction of this invention is to add storage and release functions for anti-inflammatory and other types of drugs that can be excited by light, and the improvement direction of this invention is to control the dosage and timing of drug release. Summary of the Invention

[0007] To address the above problems, the technical approach adopted by this invention is as follows: Through three coordinated drug delivery modes, intelligent, precise, and efficient drug delivery is achieved around the implant. Normally, a continuous drug release is achieved via an osmotic pump. Upon detection of inflammation, the release dose is increased through an inflammation-based release mode. When the patient bites down, the release dose is increased when occlusal and decreased when occlusal.

[0008] The specific plan is as follows: An oral abutment with sustained drug release function has three mutually cooperating drug release modes, including: a continuous release mode structure disposed on an implant integrated with bone tissue in the alveolar bone; an inflammation release mode structure disposed inside the continuous release mode structure; and a force-induced release mode structure disposed on the upper part of the continuous release mode structure and extending to the outside of the continuous release mode structure; the top of the implant covers the bottom of the continuous release mode structure.

[0009] The preferred embodiment is that the continuous release mode structure is composed of an osmotic pump, which consists of a semi-permeable membrane, a drug storage layer and a propulsion layer from the outside to the inside, and the osmotic pump is provided with multiple drug release holes. The internal structure of the propulsion layer is provided with the inflammation release mode structure; wherein, water in saliva enters the water-absorbing and expanding propulsion layer through the semi-permeable membrane, the expansion of the propulsion layer causes the pressure of the drug storage layer to increase, and the drug solution is released from the drug release orifice under pressure.

[0010] Another preferred embodiment is that the inflammation release mode structure includes: a liquid sac with a heating function, disposed inside the pusher layer; a support rod, vertically disposed inside the liquid sac and extending to the outside of the liquid sac; several springs, one end of which is connected to the portion of the support rod immersed in the liquid inside the liquid sac; several push plates, one side of which is connected to the end of the spring away from the support rod, and the other side is attached to the inner wall of the liquid sac; wherein, by heating the liquid inside the liquid sac, the springs deform, causing the push plates to move outward, and the liquid sac expands accordingly, squeezing the pusher layer and the drug storage layer, so that the drug solution is released from the drug release orifice.

[0011] Furthermore, the spring is made of shape memory alloy.

[0012] To achieve the above solution, preferably, a telescopic rod is provided through the inside of the spring to guide the spring, with one end of the telescopic rod connected to the support rod and the other end connected to the push plate.

[0013] Optionally, the heating assembly of the liquid bladder includes: a set of heating plates respectively disposed at the top and bottom of the liquid bladder; and a temperature sensor disposed at the top of the implant; wherein, after the temperature sensor detects a temperature increase due to inflammation, it controls the heating plates to heat the liquid in the liquid bladder.

[0014] Specifically, an elastic tube is connected to the outside of the drug release orifice and communicates with it, and a release hole that cooperates with the elastic tube is opened through the top of the implant.

[0015] Another preferred embodiment is that the force release mode structure includes: a piston located on the upper part of the support rod; a rope, one end of which is connected to the piston and the other end of which is connected to the elastic tube; wherein, when the patient performs a biting action, the piston is forced to move downward, the piston squeezes the osmotic pump to release the drug solution, and at the same time drives the rope to move downward, causing the elastic tube to open, so that the drug solution enters the patient's oral cavity through the elastic tube.

[0016] Furthermore, a return spring is provided between the piston and the support rod; when the piston is subjected to force and moves downward, it compresses the return spring; when the piston is not subjected to force, the return spring restores its deformation, causing the piston to move upward, which in turn drives the rope to move upward, and the rope causes the elastic tube to close.

[0017] By adopting the above technical solution, the present invention has the following technical effects: An oral abutment with drug sustained-release function has three drug release modes that work together: a continuous release mode structure, which is located in the alveolar bone and integrated with the implant; an inflammation release mode structure, which is located inside the continuous release mode structure; and a force release mode structure, which is located on the upper part of the continuous release mode structure and extends to the outside of the continuous release mode structure.

[0018] During implant restoration surgery, this invention is used in conjunction with the implant. This invention features three interconnected drug release modes to achieve precise, intelligent, and efficient drug release around the implant, ensuring the drug directly targets the affected area and minimizing its impact on other healthy oral tissues. It automatically adjusts the drug release amount and rate based on different physiological and pathological conditions. Under normal conditions, a continuous release of appropriate amounts of drug is achieved through an osmotic pump to maintain a basic therapeutic concentration. When inflammation of the peri-implant mucosa is detected, and an increase in temperature at the inflamed site is detected, the inflammation release mode increases the drug release amount to enhance the treatment effect. When the patient bites, the force release mode increases the drug release during occlusion and decreases it during opening, further supplementing the drug release. This invention significantly improves the treatment effect of peri-implant mucositis, effectively alleviates inflammatory symptoms, and promotes the repair and regeneration of peri-implant tissues. By leveraging the synergistic effect of multiple drug release mechanisms, the concentration and duration of drug action at the site of inflammation are increased, accelerating the inflammation resolution process and reducing the recurrence rate. This enhances the stability and lifespan of implants, improves the overall success rate of dental implant treatment, and provides strong support for patients to restore good oral function and aesthetics. Attached Figure Description

[0019] To more clearly illustrate the technical solutions of the embodiments of this application, the accompanying drawings used in the embodiments will be briefly described below.

[0020] Figure 1 This is a schematic diagram of the structure of an oral abutment with drug sustained-release function provided in an embodiment of this application; Figure 2 This is an exploded schematic diagram of an oral abutment with drug sustained-release function provided in an embodiment of this application; Figure 3 This is a schematic diagram of the use of an oral abutment with drug sustained-release function provided in an embodiment of this application; Figure 4 This is a schematic diagram of the continuous release mode structure provided in the embodiments of this application; Figure 5 This is a schematic diagram showing the location of the inflammatory release mode structure provided in the embodiments of this application; Figure 6 This is a schematic diagram of the internal structure of the liquid bladder provided in the embodiments of this application; Figure 7 This is a schematic diagram showing the position of the telescopic rod provided in an embodiment of this application; Figure 8 This is a schematic diagram showing the position of the heating plate provided in an embodiment of this application; Figure 9 This is a schematic diagram showing the position of the force release mode structure provided in the embodiments of this application; Figure 10This is a schematic diagram of the piston and support rod provided in an embodiment of this application; Figure 11 This is provided by the embodiments of this application. Figure 3 Cross-sectional view; Figure 12 This is provided by the embodiments of this application. Figure 11 Enlarged view of section A in the middle; Icons: Continuous release mode structure 100; Drug storage layer 101; Pushing layer 102; Semi-permeable membrane 103; Drug release orifice 104; Elastic tube 105; Inflammation release mode structure 200; Liquid bladder 201; Support rod 202; Push plate 203; Telescopic rod 204; Spring 205; Heating plate 206; Temperature sensor 207; Battery 208; Force-induced release mode structure 300; Piston 301; Rope 302; Reset spring 303; Implant 400. Detailed Implementation

[0021] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the appendices in the embodiments of this application will be described below. Figure 1-12 The technical solutions in the embodiments of this application are clearly and completely described. Obviously, the described embodiments are some embodiments of this application, but not all embodiments.

[0022] It should be noted that similar labels and letters in the following figures indicate similar items. Therefore, once an item is defined in one figure, it does not need to be further defined and explained in subsequent figures.

[0023] In the description of this application, it should be noted that the terms "center", "upper", "lower", "vertical", "horizontal", "inner", "outer", etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings, or the orientation or positional relationship commonly used when the product of this application is in use. They are only for the convenience of describing this application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this application.

[0024] In the description of this application, it should also be noted that, unless otherwise expressly specified and limited, the terms “set up,” “install,” “connect,” and “link” should be interpreted broadly. Example

[0025] The inventors' research revealed that traditional treatments for peri-implant mucositis primarily involve local irrigation, medication application, or oral antibiotics. Local irrigation and medication application are inconvenient, and the medication's residence time at the inflamed site is short, making it difficult to maintain an effective drug concentration. Oral antibiotics may cause systemic adverse reactions, and the drug concentration is significantly reduced by the time it reaches the peri-implant inflamed area, limiting their efficacy. Existing patented oral abutments mostly release a constant amount of drug, which is ineffective in treating the inflamed area and in relieving sharp pain during biting. Therefore, this application provides an oral abutment with sustained-release function, controllable dosage, controllable timing of drug administration, precision, and intelligence.

[0026] A dental implant system typically consists of three parts: the implant, which is inserted into the alveolar bone and integrates with the bone tissue; the artificial crown; and the implant abutment, which connects the implant and the artificial crown. The crown passes through the implant and extends into the oral cavity, while the abutment is located inside the crown.

[0027] In the embodiments of this application, please refer to Figure 1 , Figure 2 and Figure 3 , Figure 1 This is a schematic diagram of the structure of an oral abutment with drug sustained-release function provided in an embodiment of this application; Figure 2 This is an exploded schematic diagram of an oral abutment with drug sustained-release function provided in an embodiment of this application; Figure 3 This is a schematic diagram illustrating the use of a dental abutment with drug sustained-release function provided in an embodiment of this application. A dental abutment with drug sustained-release function has three mutually cooperating drug release modes, including: a continuous release mode structure 100, disposed on an implant 400 implanted in the alveolar bone and integrated with the bone tissue; an inflammation release mode structure 200, disposed inside the continuous release mode structure 100; and a force-induced release mode structure 300, disposed on the upper part of the continuous release mode structure 100 and extending to the outside of the continuous release mode structure 100; the top of the implant 400 covers the bottom of the continuous release mode structure 100.

[0028] During implant restoration surgery, this invention is used in conjunction with the implant. This invention features three interconnected drug release modes to achieve precise, intelligent, and efficient drug release around the implant, ensuring the drug directly targets the affected area and minimizing its impact on other healthy oral tissues. It automatically adjusts the drug release amount and rate based on different physiological and pathological conditions. Under normal conditions, a continuous release of appropriate amounts of drug is achieved through an osmotic pump to maintain a basic therapeutic concentration. When inflammation of the peri-implant mucosa is detected, and an increase in temperature at the inflamed site is detected, the inflammation release mode structure 200 increases the drug release amount to enhance the treatment effect. When the patient periodically presses the occlusal force, the force release mode structure 300 increases the drug release amount when occlusal and decreases it when open, further supplementing the drug release. This invention significantly improves the treatment effect of peri-implant mucositis, effectively alleviates inflammatory symptoms, and promotes the repair and regeneration of peri-implant tissues. By leveraging the synergistic effect of multiple drug release mechanisms, the concentration and duration of drug action at the site of inflammation are increased, accelerating the inflammation resolution process and reducing the recurrence rate. This enhances the stability and lifespan of implants, improves the overall success rate of dental implant treatment, and provides strong support for patients to restore good oral function and aesthetics.

[0029] In the embodiments of this application, please refer to Figure 4 , Figure 4 This is a schematic diagram of the continuous release mode structure provided in the embodiments of this application. The continuous release mode structure 100 is composed of an osmotic pump, which consists of a semi-permeable membrane 103, a drug storage layer 101, and a propulsion layer 102 from the outside to the inside. The osmotic pump has a plurality of drug release holes 104 through it. The inflammation release mode structure 200 is provided inside the propulsion layer 102.

[0030] An osmotic pump is a drug delivery device that uses the principle of osmotic pressure to control drug release. An osmotic pump consists of a drug reservoir 101, a driving layer 102, a semi-permeable membrane 103 that allows only small molecules such as water molecules to pass freely, and drug release orifices 104. The driving layer 102 and the drug reservoir 101 are double-layered. The drug reservoir 101 contains the drug and is surrounded by the semi-permeable membrane 103, which has drug release orifices 104. When in contact with water, water passes through the semi-permeable membrane 103 into the driving layer 102, causing the osmotic active substances in the driving layer 102 to absorb water and swell, generating high osmotic pressure. Driven by this osmotic pressure, the drug solution is continuously and at a constant rate released from the drug release orifices 104. An osmotic pump can store a sufficient amount of drug to meet the needs of a treatment cycle and has good sealing properties to prevent drug leakage and deterioration. Osmotic pumps are common existing technology and can be implemented by those skilled in the art; therefore, they will not be described in detail here.

[0031] Specifically, the outer side of the drug release orifice 104 is connected to one end of an elastic tube 105 that communicates with it. The hollow elastic tube 105 is made of rubber and has a certain support and elasticity. The inside of the elastic tube 105 is connected to the inside of the drug release orifice 104. One end of the elastic tube 105 is integrally formed with the osmotic pump. The top of the implant 400 is provided with a release hole that cooperates with the elastic tube 105.

[0032] In the embodiments of this application, please refer to Figure 5 , Figure 6 , Figure 7 and Figure 8 , Figure 5 This is a schematic diagram showing the location of the inflammatory release mode structure provided in the embodiments of this application; Figure 6 This is a schematic diagram of the internal structure of the liquid bladder provided in the embodiments of this application; Figure 7 This is a schematic diagram showing the position of the telescopic rod provided in an embodiment of this application; Figure 8 This is a schematic diagram of the position of the heating plate provided in this embodiment. The inside of the pushing layer 102 is hollow and is used to house the inflammation release mode structure 200. The inflammation release mode structure 200 includes: a liquid sac 201 with heating function, disposed inside the pushing layer 102; a support rod 202, vertically disposed inside the liquid sac 201 and extending to the outside of the liquid sac 201; several springs 205, one end of which is connected to the part of the support rod 202 immersed in the liquid inside the liquid sac 201; several push plates 203, one side of which is connected to the end of the spring 205 away from the support rod 202, and the other side is attached to the inner wall of the liquid sac 201; wherein, by heating the liquid inside the liquid sac 201, the springs 205 deform, driving the push plates 203 to move outward, and the liquid sac 201 expands accordingly, squeezing the pushing layer 102 and the drug storage layer 101, so that the drug solution is released from the drug release hole 104.

[0033] Specifically, the upper and lower sides of the liquid bladder 201 are made of rigid material, while the sides are made of soft material. On the one hand, the upper part can be sealed with the support rod 202 so that the liquid inside the liquid bladder 201 will not be exposed. On the other hand, it can limit the liquid bladder 201 from expanding to the upper and lower sides, and only expand to the sides.

[0034] Furthermore, spring 205 is made of shape memory alloy. It is made of materials with shape memory effect, such as nickel-titanium alloy. At room temperature, spring 205 is in a specific initial shape and state. When heated, the alloy spring 205 changes shape, expands outward, and generates an outward thrust.

[0035] To achieve the above solution, preferably, in order to guide the spring 205, a telescopic rod 204 passes through the interior of the spring 205, with one end of the telescopic rod 204 connected to the support rod 202 and the other end connected to the push plate 203. The telescopic rod 204 is a common prior art, which can be implemented by those skilled in the art, and will not be described in detail here.

[0036] This application does not limit the specific number and size of the push plate 203. In practical applications, those skilled in the art should ensure that the push plate 203 can be placed inside the liquid bladder 201 and can be evenly squeezed to the side of the push layer 102. The number of springs 205 should match the number of push plates 203. At least one set of springs 205 needs to be connected to each push plate 203. The set of springs 205 is placed on the upper and lower sides respectively so that the push plate 203 is subjected to a uniform pushing force. The number of telescopic rods 204 should match the number of springs 205. Each spring 205 needs to be limited by a telescopic rod 204 to ensure the direction of the pushing force.

[0037] Optionally, the heating assembly of the liquid sac 201 includes: a set of heating plates 206, respectively disposed at the top and bottom of the liquid sac 201; and a temperature sensor 207 disposed at the top of the implant 400; wherein, after the temperature sensor 207 detects the temperature rise caused by inflammation, it controls the heating plates 206 to heat the liquid in the liquid sac 201.

[0038] The heating plate 206 is a common existing technology that can be implemented by those skilled in the art, and will not be described in detail here.

[0039] Heating plates 206 are fixedly connected to the top and bottom of liquid bladders 201. Support rods 202 are perpendicular to heating plates 206 and fixedly connected to them. A battery 208 is located inside the support rod 202 near the heating plate 206, providing power to the heating plates 206. To further ensure heating performance, waterproof coatings are applied to the outside of the battery 208 and the heating plates 206. Using a battery 208 to power the heating plates 206 is a common existing technology, readily achievable by those skilled in the art, and will not be elaborated upon here.

[0040] Temperature sensor 207 and heating plate 206 controlled by temperature sensor 207 are common existing technologies that can be implemented by those skilled in the art, and will not be described in detail here.

[0041] In the embodiments of this application, please refer to Figure 9 , Figure 10 , Figure 11 and Figure 12 , Figure 9 This is a schematic diagram showing the position of the force release mode structure provided in the embodiments of this application; Figure 10 This is a schematic diagram of the piston and support rod provided in an embodiment of this application; Figure 11 This is provided by the embodiments of this application. Figure 3 Cross-sectional view; Figure 12 This is provided by the embodiments of this application. Figure 11Enlarged view of part A. The force-releasing mode structure 300 includes: a piston 301, which is I-shaped and located on the upper part of the support rod 202; a rope 302, one end of which is connected to the piston 301 and the other end of which is connected to the elastic tube 105; wherein, when the patient bites, the piston 301 is forced to move downward, the piston 301 squeezes the osmotic pump to release the drug solution, and at the same time drives the rope 302 to move downward, causing the elastic tube 105 to open, so that the drug solution enters the patient's oral cavity through the elastic tube 105.

[0042] Furthermore, a return spring 303 is provided between the piston 301 and the support rod 202; the upper end of the support rod 202 (i.e. the part exposed in the liquid bladder 201) passes through the bottom of the piston 301, and the upper end of the support rod 202 passes through the return spring 303. One end of the return spring 303 is fixedly connected to the liquid bladder 201, and the other end is fixedly connected to the inside of the piston 301.

[0043] Several ropes 302 are fixedly connected to the bottom edge of the piston 301. Each rope 302 is symmetrically bent on one side. The bent side is sleeved on the lower part of the elastic tube 105, so that the elastic tube 105 can be opened and closed by the up and down movement of the ropes 302. The non-bent side is fixedly connected to the bottom edge of the piston 301.

[0044] In this application, the specific number of ropes 302 should be less than the number of elastic tubes 105, and it should be ensured that the continuous release mode structure 100 can release the normal amount of drug under normal non-engaging state.

[0045] When piston 301 is subjected to force and moves downward, it compresses return spring 303; when piston 301 is not subjected to force, return spring 303 restores its deformation, causing piston 301 to move upward, which in turn causes rope 302 to move upward, and rope 302 to close elastic tube 105.

[0046] Application process Peri-implantitis is a possible complication after dental implantation. The core treatment goal is to control infection, eliminate inflammation, and restore the health of the tissues surrounding the implant. Specific treatment plans need to be individualized based on the severity of inflammation, bone resorption, and other factors.

[0047] Traditional treatments for peri-implantitis typically involve local irrigation, topical medication, or oral antibiotics. Local irrigation and topical medication are inconvenient to perform, and the medication remains at the inflamed site for a short time, making it difficult to maintain an effective drug concentration. Oral antibiotics, on the other hand, can cause systemic adverse reactions, and their concentration is significantly reduced by the time they reach the peri-implantitis area, limiting their effectiveness.

[0048] Based on the limitations of the above treatment methods, this application provides an oral abutment with drug sustained-release function, which is used in the following ways: When the oral abutment is in the oral environment, under normal conditions, water in saliva enters the water-absorbing and expanding push layer 102 through the semipermeable membrane 103. The expansion of the push layer 102 causes the pressure of the drug storage layer 101 to increase. The drug solution will then be released from the drug release orifice 104 under pressure, thereby achieving the continuous release of an appropriate amount of drug and maintaining the basic treatment concentration.

[0049] When the temperature sensor 207 detects an increase in temperature at the site of inflammation in the peri-implant mucosa, it controls the heating plate 206 to heat the liquid in the sac 201. The high temperature causes the spring 205 to deform, and under the limiting action of the telescopic rod 204, it drives the push plate 203 to move outward. The sac 201 expands accordingly, squeezing the pushing layer 102 and the drug storage layer 101, causing the drug solution to be released from the drug release hole 104, thereby increasing the amount of drug released and enhancing the therapeutic effect on the inflamed site.

[0050] When the patient performs the pressing and biting action at regular intervals, the piston 301 moves downward under force, squeezing the return spring 303. The piston 301 squeezes the osmotic pump to release the drug solution, and at the same time, it drives the rope 302 to move downward, causing the elastic tube 105 to open, allowing the drug solution to enter the patient's oral cavity through the elastic tube 105, further supplementing the drug release. When the piston 301 is no longer under force, the return spring 303 returns to its original deformation, causing the piston 301 to move upward, driving the rope 302 to move upward, and the rope 302 closes the elastic tube 105.

[0051] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. An oral abutment with drug sustained-release function, characterized in that, It has three mutually coordinating drug release modes, including: A continuous release pattern structure (100) is disposed on an implant (400) that is integrated with bone tissue in the alveolar bone; An inflammatory release mode structure (200) is disposed inside the sustained release mode structure (100); A force-releasing mode structure (300) is disposed on the upper part of the continuous release mode structure (100) and extends to the outside of the continuous release mode structure (100); The top of the implant (400) covers the bottom of the continuous release pattern structure (100).

2. The oral abutment with drug sustained-release function according to claim 1, characterized in that, The continuous release mode structure (100) is composed of an osmotic pump, which consists of a semi-permeable membrane (103), a drug storage layer (101) and a propulsion layer (102) from the outside to the inside. Multiple drug release holes (104) are provided through the osmotic pump. The internal structure of the propulsion layer (102) is provided with the inflammation release mode structure (200); In this process, the water in the saliva enters the water-absorbing and expanding push layer (102) through the semi-permeable membrane (103). The expansion of the push layer (102) causes the pressure of the drug storage layer (101) to increase, and the drug solution is released from the drug release orifice (104) under the pressure drive.

3. The oral abutment with drug sustained-release function according to claim 2, characterized in that, The inflammation release pattern structure (200) includes: The liquid bladder (201), which has a heating function, is located inside the push layer (102); A support rod (202) is vertically disposed inside the liquid bladder (201) and extends to the outside of the liquid bladder (201); Several springs (205) have one end connected to the portion of the support rod (202) that is immersed in the liquid in the liquid bladder (201); Several push plates (203) are connected on one side to the end of the spring (205) away from the support rod (202), and on the other side to the inner wall of the liquid bladder (201); In this process, by heating the liquid inside the liquid bladder (201), the spring (205) is deformed, which drives the pusher plate (203) to move outward. The liquid bladder (201) expands accordingly, squeezing the pusher layer (102) and the drug storage layer (101), so that the drug solution is released from the drug release hole (104).

4. The oral abutment with drug sustained-release function according to claim 3, characterized in that, The spring (205) is made of shape memory alloy.

5. The oral abutment with drug sustained-release function according to claim 4, characterized in that, A telescopic rod (204) is provided through the inside of the spring (205) to guide the spring (205). One end of the telescopic rod (204) is connected to the support rod (202), and the other end is connected to the push plate (203).

6. The oral abutment with drug sustained-release function according to claim 3, characterized in that, The heating assembly of the liquid bladder (201) includes: A set of heating plates (206) are respectively disposed at the top and bottom of the liquid bladder (201); A temperature sensor (207) is located on top of the implant (400); When the temperature sensor (207) detects a temperature rise due to inflammation, it controls the heating plate (206) to heat the liquid in the liquid sac (201).

7. The oral abutment with drug sustained-release function according to claim 3, characterized in that, The drug release orifice (104) is connected to an elastic tube (105) that communicates with it, and the top of the implant (400) is provided with a release hole that cooperates with the elastic tube (105).

8. The oral abutment with drug sustained-release function according to claim 7, characterized in that, The force release mode structure (300) includes: Piston (301) is located on the upper part of the support rod (202); The rope (302) is connected at one end to the piston (301) and at the other end to the elastic tube (105); When the patient bites down, the piston (301) moves downward under force, and the piston (301) squeezes the osmotic pump to release the drug solution. At the same time, it drives the rope (302) to move downward, so that the elastic tube (105) opens and the drug solution enters the patient's oral cavity through the elastic tube (105).

9. The oral abutment with drug sustained-release function according to claim 8, characterized in that, A return spring (303) is provided between the piston (301) and the support rod (202). When the piston (301) is subjected to force and moves downward, it compresses the return spring (303). When the piston (301) is not under force, the return spring (303) restores its deformation, causing the piston (301) to move upward, which in turn causes the rope (302) to move upward, and the rope (302) causes the elastic tube (105) to close.

Images